Bio-Techne Corporation logo
TECHBio-Techne Corporation

EV/EBITDA Ratio: 44.17x

popular:market cap|pe ratio|revenue|price history|total return

Is the EV/EBITDA ratio high or low?

The EV/EBITDA ratio of 44.17x is 14% above its 5-year average of 38.87x, around the middle of its 5-year range (21.74x–68.95x).

As of Saturday, June 27, 2026. 10.60% above its 12-month average of 39.94x.

EV/Sales|P/E Ratio|EBITDA|All Metrics
TECH EV/EBITDA Ratio

TECH EV/EBITDA Ratio Chart

44.17x
+43.97% 1Y
TECH EV/EBITDA Ratio

TECH Average EV/EBITDA Ratio Chart

TECH EV/EBITDA Ratio

TECH Current vs Average EV/EBITDA Ratio Chart

TECH EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

44.17x

EV/EBITDA RATIO AVG TTM

39.94x

EV/EBITDA RATIO AVG 3Y

35.25x

EV/EBITDA RATIO AVG 5Y

36.51x

EV/EBITDA RATIO AVG 10Y

35.31x

EV/EBITDA RATIO AVG 15Y

30.12x

EV/EBITDA RATIO AVG 20Y

26.15x

CURRENT VS TTM AVG

+10.60%

CURRENT VS 3Y AVG

+25.32%

CURRENT VS 5Y AVG

+20.97%

CURRENT VS 10Y AVG

+25.09%

CURRENT VS 15Y AVG

+46.64%

CURRENT VS 20Y AVG

+68.88%

TECH Competitors' EV/EBITDA Ratio

NAMEMARKET CAPEV/EBITDA RATIOTTM3Y5Y
Bio-Techne Corporation (TECH)$11.12B44.17x39.94x35.25x36.51x
Insulet Corp. (PODD)vs ›$10.96B19.03x37.29x57.29x93.26x
Baxter International Inc. (BAX)vs ›$11.38B28.35x22.28x20.52x19.84x
Molina Healthcare, Inc. (MOH)vs ›$11.79B13.59x6.78x8.89x10.39x
Walgreens Boots Alliance, Inc. (WBA)vs ›$10.37BN/A32.35x25.45x22.17x
Charles River Laboratories International, Inc. (CRL)vs ›$10.20B16.11x17.78x15.97x17.66x
Tempus AI, Inc. (TEM)vs ›$9.80BN/AN/AN/AN/A
Henry Schein, Inc. (HSIC)vs ›$9.68B12.78x11.33x11.83x11.68x
Revvity, Inc. (RVTY)vs ›$12.61B19.57x17.15x18.80x17.33x
Align Technology, Inc. (ALGN)vs ›$12.78B13.75x14.40x20.86x25.85x

EV/EBITDA vs. its own history

At 44.2, EV/EBITDA is richer than usual, sitting higher than 90% of its 20-year history.

20-year low

10.0

median

21.5

20-year high

69.0

cheaperricher

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBITDA Ratio FAQ

What is the EV/EBITDA ratio for Bio-Techne Corporation (TECH)?
The EV/EBITDA ratio for TECH stock is 44.17x.
Is Bio-Techne Corporation's EV/EBITDA ratio high or low?
The EV/EBITDA ratio of 44.17x is 14% above its 5-year average of 38.87x, around the middle of its 5-year range (21.74x–68.95x).
What is the TTM average EV/EBITDA ratio for Bio-Techne Corporation (TECH)?
The TTM average EV/EBITDA ratio for TECH stock is 39.94x.
What is the 3Y average EV/EBITDA ratio for Bio-Techne Corporation (TECH)?
The 3Y average EV/EBITDA ratio for TECH stock is 35.25x.
What is the 5Y average EV/EBITDA ratio for Bio-Techne Corporation (TECH)?
The 5Y average EV/EBITDA ratio for TECH stock is 36.51x.
What is the 10Y average EV/EBITDA ratio for Bio-Techne Corporation (TECH)?
The 10Y average EV/EBITDA ratio for TECH stock is 35.31x.
What is the 15Y average EV/EBITDA ratio for Bio-Techne Corporation (TECH)?
The 15Y average EV/EBITDA ratio for TECH stock is 30.12x.
What is the 20Y average EV/EBITDA ratio for Bio-Techne Corporation (TECH)?
The 20Y average EV/EBITDA ratio for TECH stock is 26.15x.

TECH EV/EBITDA Ratio History

DATEEV/EBITDA RATIO
2026-06-2644.17x
2026-06-2543.99x
2026-06-2436.69x
2026-06-2335.07x
2026-06-2234.67x
2026-06-1836.11x
2026-06-1734.29x
2026-06-1634.93x
2026-06-1535.01x
2026-06-1233.67x
2026-06-1133.68x
2026-06-1032.75x
2026-06-0933.93x
2026-06-0832.84x
2026-06-0532.43x
2026-06-0433.17x
2026-06-0331.73x
2026-06-0231.06x
2026-06-0131.69x
2026-05-2932.24x
2026-05-2831.72x
2026-05-2730.02x
2026-05-2629.95x
2026-05-2230.10x
2026-05-2129.58x
2026-05-2029.16x
2026-05-1928.40x
2026-05-1827.76x
2026-05-1527.06x
2026-05-1427.95x
2026-05-1328.04x
2026-05-1229.61x
2026-05-1129.61x
2026-05-0830.19x
2026-05-0731.76x
2026-05-0629.60x
2026-05-0541.13x
2026-05-0439.75x
2026-05-0139.95x
2026-04-3040.16x
2026-04-2937.76x
2026-04-2838.87x
2026-04-2740.01x
2026-04-2439.36x
2026-04-2337.94x
2026-04-2242.48x
2026-04-2143.25x
2026-04-2043.90x
2026-04-1742.94x
2026-04-1641.61x
2026-04-1542.41x
2026-04-1442.54x
2026-04-1341.73x
2026-04-1040.32x
2026-04-0940.34x
2026-04-0840.08x
2026-04-0739.10x
2026-04-0639.08x
2026-04-0238.60x
2026-04-0138.85x
2026-03-3137.98x
2026-03-3037.83x
2026-03-2737.05x
2026-03-2638.30x
2026-03-2538.29x
2026-03-2438.10x
2026-03-2337.80x
2026-03-2037.43x
2026-03-1937.51x
2026-03-1836.95x
2026-03-1737.13x
2026-03-1635.53x
2026-03-1336.98x
2026-03-1237.42x
2026-03-1138.95x
2026-03-1038.38x
2026-03-0939.84x
2026-03-0639.14x
2026-03-0540.57x
2026-03-0441.96x
2026-03-0341.35x
2026-03-0241.94x
2026-02-2742.78x
2026-02-2642.01x
2026-02-2541.97x
2026-02-2441.78x
2026-02-2339.76x
2026-02-2041.72x
2026-02-1942.24x
2026-02-1843.01x
2026-02-1742.42x
2026-02-1343.44x
2026-02-1243.16x
2026-02-1145.94x
2026-02-1046.90x
2026-02-0947.39x
2026-02-0648.31x
2026-02-0547.66x
2026-02-0449.66x
2026-02-0347.93x
2026-02-0248.38x
2026-01-3047.54x
2026-01-2947.46x
2026-01-2848.61x
2026-01-2750.54x
2026-01-2650.11x
2026-01-2350.49x
2026-01-2251.57x
2026-01-2152.82x
2026-01-2051.51x
2026-01-1650.86x
2026-01-1551.79x
2026-01-1450.66x
2026-01-1349.19x
2026-01-1249.33x
2026-01-0948.71x
2026-01-0847.90x
2026-01-0748.24x
2026-01-0648.40x
2026-01-0546.78x
2026-01-0244.33x
2025-12-3143.72x
2025-12-3043.95x
2025-12-2944.03x
2025-12-2644.02x
2025-12-2444.00x
2025-12-2344.04x
2025-12-2243.83x
2025-12-1943.33x
2025-12-1842.48x
2025-12-1742.40x
2025-12-1642.73x
2025-12-1543.63x
2025-12-1243.50x
2025-12-1144.77x
2025-12-1045.18x
2025-12-0943.73x
2025-12-0844.79x
2025-12-0545.80x
2025-12-0447.14x
2025-12-0347.35x
2025-12-0246.72x
2025-12-0147.30x
2025-11-2847.85x
2025-11-2647.93x
2025-11-2548.82x
2025-11-2447.11x
2025-11-2145.69x
2025-11-2043.66x
2025-11-1943.00x
2025-11-1843.24x
2025-11-1743.58x
2025-11-1444.13x
2025-11-1345.13x
2025-11-1245.60x
2025-11-1143.99x
2025-11-1042.74x
2025-11-0742.71x
2025-11-0643.27x
2025-11-0544.54x
2025-11-0446.19x
2025-11-0346.30x
2025-10-3147.26x
2025-10-3046.08x
2025-10-2946.86x
2025-10-2848.27x
2025-10-2748.50x
2025-10-2449.72x
2025-10-2349.83x
2025-10-2248.16x
2025-10-2147.92x
2025-10-2047.24x
2025-10-1746.74x
2025-10-1646.55x
2025-10-1545.07x
2025-10-1444.84x
2025-10-1345.12x
2025-10-1044.39x
2025-10-0945.30x
2025-10-0845.79x
2025-10-0744.78x
2025-10-0646.79x
2025-10-0347.54x
2025-10-0246.91x
2025-10-0145.32x
2025-09-3042.17x
2025-09-2939.67x
2025-09-2639.39x
2025-09-2538.39x
2025-09-2438.93x
2025-09-2340.18x
2025-09-2240.27x
2025-09-1940.35x
2025-09-1840.23x
2025-09-1739.15x
2025-09-1639.34x
2025-09-1539.23x
2025-09-1238.96x
2025-09-1140.39x
2025-09-1038.74x
2025-09-0941.12x
2025-09-0841.05x
2025-09-0541.27x
2025-09-0440.18x
2025-09-0340.49x
2025-09-0240.55x
2025-08-2941.44x
2025-08-2841.22x
2025-08-2742.60x
2025-08-2643.02x
2025-08-2542.96x
2025-08-2243.24x
2025-08-2131.35x
2025-08-2031.54x
2025-08-1931.84x
2025-08-1830.95x
2025-08-1531.13x
2025-08-1431.21x
2025-08-1331.75x
2025-08-1230.69x
2025-08-1129.19x
2025-08-0829.34x
2025-08-0729.19x
2025-08-0629.03x
2025-08-0531.71x
2025-08-0431.85x
2025-08-0131.85x
2025-07-3131.76x
2025-07-3033.44x
2025-07-2933.53x
2025-07-2833.91x
2025-07-2534.04x
2025-07-2433.86x
2025-07-2332.09x
2025-07-2230.86x
2025-07-2129.26x
2025-07-1830.24x
2025-07-1730.95x
2025-07-1630.11x
2025-07-1529.90x
2025-07-1430.58x
2025-07-1131.43x
2025-07-1031.58x
2025-07-0930.56x
2025-07-0830.61x
2025-07-0729.97x
2025-07-0330.87x
2025-07-0230.89x
2025-07-0130.27x
2025-06-3029.92x
2025-06-2730.14x
2025-06-2630.68x
2025-06-2530.17x
2025-06-2429.10x
2025-06-2328.71x
2025-06-2029.04x
2025-06-1829.18x
2025-06-1728.82x
2025-06-1630.02x
2025-06-1329.40x

Showing the most recent 260 of 5,032 data points. The chart above shows the full history.

Related Metrics

EV/SalesP/E RatioEBITDAAll Metrics

About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Minneapolis, MN
3,100 employees
www.bio-techne.com
Healthcare / Biotechnology
Sector
Healthcare
Industry
Biotechnology
CEO
Kim Kelderman
View full financials